This paper focuses on the COVID-19 vaccines authorised for use in the European Union, and explores the mechanisms in place to control vaccine safety and to compensate injured patients, mainly in the context of European law. Based on these considerations, the paper concludes that the refusal by some potential vaccinees to take the vaccine based on safety concerns is ungrounded and an indication of unrealistic expectations, but that in order to build public trust proper compensation mechanisms should be in place.
Purchase
Buy instant access (PDF download and unlimited online access):
Institutional Login
Log in with Open Athens, Shibboleth, or your institutional credentials
Personal login
Log in with your brill.com account
All Time | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 1881 | 619 | 42 |
Full Text Views | 979 | 18 | 1 |
PDF Views & Downloads | 1329 | 32 | 2 |
This paper focuses on the COVID-19 vaccines authorised for use in the European Union, and explores the mechanisms in place to control vaccine safety and to compensate injured patients, mainly in the context of European law. Based on these considerations, the paper concludes that the refusal by some potential vaccinees to take the vaccine based on safety concerns is ungrounded and an indication of unrealistic expectations, but that in order to build public trust proper compensation mechanisms should be in place.
All Time | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 1881 | 619 | 42 |
Full Text Views | 979 | 18 | 1 |
PDF Views & Downloads | 1329 | 32 | 2 |